CILO CYBIN HOLDINGS LIMITED - Trading Statement

Trading Statement

Cilo Cybin Holdings Limited
Incorporated in the Republic of South Africa
(Registration number 2022/320351/06)
Share code: CCC  ISIN: ZAE000310397
Listed on the General Segment of the JSE
("Cilo Cybin" or "the Company")


TRADING STATEMENT


In terms of paragraph 3.4(b) of the JSE Limited Listings Requirements, a listed company is required to
publish a trading statement as soon as it is satisfied that a reasonable degree of certainty exists that the
financial results for the period to be reported on will differ by at least 20% from the previous corresponding
period.

Shareholders are advised that Cilo Cybin is in the process of finalising its results for the six month period
ended 30 September 2025 ("interim results") and anticipates that it will report:

 -   a basic loss per share of between 138.30 cents and 138.48 cents, compared to the basic earnings
     per share of 0.87 cents for the previous corresponding period, which represents an expected
     decrease in excess of 100%; and
 -   a headline loss per share of between 138.30 cents and 138.48 cents compared to the headline
     earnings per share of 0.87 cents for the previous corresponding period, which represents an expected
     decrease in excess of 100%.

The board of directors of Cilo Cybin hereby reminds shareholders that, on 23 December 2024, the
Company entered into a Share Purchase Agreement with the shareholders of Cilo Cybin Pharmaceutical
Proprietary Limited ("CC Pharmaceutical"), in terms of which the Company acquired 100% of the issued
shares in CC Pharmaceutical for an aggregate consideration of R845 million, settled through the issue of
Cilo Cybin shares. The effective date of the acquisition of CC Pharmaceutical was 30 September 2025.

In line with the acquisition of CC Pharmaceutical as a viable asset, the Company has incurred substantial
once-off acquisition-related costs. These include, but are not limited to, fees for independent fair and
reasonable assessments, corporate advisory, legal advisory, accounting, and tax advisory services. The
acquisition was considered to be a reverse acquisition in terms of IFRS meaning that CC Pharmaceutical
was deemed to be the accounting acquirer and Cilo Cybin the accounting acquiree due to the fact that
Cilo Cybin did not meet the definition of a "business" in terms of IFRS 3. This resulted in the group having
to recognise a once off IFRS 2 share based payment/listing expense in the Statement of Profit and Loss
of R217 480 665. These non-recurring costs have been the primary contributor to the decrease in earnings
and headline earnings per share for the period under review.

The financial information on which this trading statement is based has not been reviewed or reported on
by the Company's auditors. The interim results are expected to be released on SENS on or about Friday,
21 November 2025.


Johannesburg
14 November 2025

Sponsor
Merchantec Capital

Date: 14-11-2025 02:21:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.